History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti arrhythmic medication. Patients with significant cardiovascular disease are excluded, including:\r\n* Myocardial infarction, severe angina, or unstable angina within months prior to administration of first dose of study drug\r\n* History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)\r\n* Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)\r\n* Coronary or peripheral artery bypass graft within months of screening\r\n* History of class III or IV congestive heart failure, as defined by the New York Heart Association Current cardiac arrhythmic condition requiring concurrent use of anti-arrhythmic drug; rate controlled atrial fibrillation is allows Patients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects History/presence of arrhythmia (even controlled) on chemical anti-arrhythmic(s) must have cardiac consult to ensure the subject could safely proceed with protocol requirements Current cardiac arrhythmia requiring concurrent use of anti-arrhythmic drugs Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Patients with cardiac ventricular arrhythmias requiring anti-arrhythmic therapy are not eligible History of cardiac ventricular arrhythmias requiring anti-arrhythmic therapy within past months Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for > month prior to first dose of study drugs are eligible) Unstable cardiac arrhythmias requiring anti-arrhythmic therapy. Patients with arrhythmia under control with anti-arrhythmic therapy such as beta-blockers or digoxin are eligible. > Class II Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Patients on anti-arrhythmic drugs Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy clinically significant symptomatic arrhythmia despite anti-arrhythmic therapy. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Patients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects Patients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects Anti-arrhythmic and heart rate lowering drugs. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Significant cardiovascular disease including:\r\n* Active, clinically symptomatic left ventricular failure\r\n* Uncontrolled symptomatic hypertension that cannot be controlled with anti-hypertensive agents\r\n* Myocardial infarction, severe angina, or unstable angina within months prior to administration of first dose of study drug\r\n* History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) \r\n* Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication) \r\n* Coronary or peripheral artery bypass graft within months of screening Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication) Need for anti-arrhythmic therapy for a ventricular arrhythmias Patients with cardiac arrhythmias must not be receiving anti-arrhythmic medication at time of study entry (or while on study). High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade atrioventricular [AV]-block, supra-ventricular arrhythmias which are not adequately rate-controlled) that require current treatment with the following anti-arrhythmic drugs: flecainide, moricizine or propafenone Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Patients on anti-arrhythmic drugs